NEW YORK (GenomeWeb News) – Vermillion expects to raise $43 million in gross proceeds from a private placement of around 2.3 million shares with a group of unnamed investors.

The Fremont, Calif.-based molecular diagnostics firm is currently operating under Chapter 11 bankruptcy protection. It said that the private placement is subject to approval of Vermillion's reorganization plan by the US Bankruptcy Court in Delaware, and would take effect on or about Jan. 7, 2010, when a hearing on the reorganization plan is scheduled.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.